Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02999477 · ClinicalTrials.gov registry record · Phase 1

A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer

A Phase 1 study of Breast Cancer, sponsored by Adrienne G. Waks.

Completed
Registry status
Phase 1
Development phase
32
Enrollment target
1
Study location

NCT02999477 is a Phase 1 study of Breast Cancer that has completed, run by Adrienne G. Waks. The registered enrollment target is 32 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02999477, a Phase 1 study of Breast Cancer, has completed, sponsored by Adrienne G. Waks.

COMPLETED
Registry status
Phase 1
Development phase
32 participants
Enrollment target
1
Study location

Study Summary

This research study is exploring chemotherapy in combination with immunotherapy (a therapy that uses the body's own immune system to control cancer) as a possible treatment for hormone receptor positive breast cancer. The interventions involved in this study are: * Pembrolizumab (MK-3475; Keytruda™) * Nab-Paclitaxel (Abraxane

Conditions Studied

Breast Cancer

Interventions

  • DRUG Pembrolizumab
  • PROCEDURE Biopsy
  • DRUG Nab-Paclitaxel

Study Locations (1)

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2017-02-23
Est. Completion 2026-01-08
Phase Phase 1

Sponsor

Adrienne G. Waks

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02999477

The ClinicalTrials.gov registry entry for NCT02999477 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Adrienne G. Waks, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.

NCT02999477 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02999477 about?

NCT02999477 is a clinical study titled "A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer". This research study is exploring chemotherapy in combination with immunotherapy (a therapy that uses the body's own immune system to control cancer) as a possible treatment for hormone receptor positive breast cancer. The interventions involved in this study are: * Pembrolizumab (MK-3475; Keytruda...

What is the current status of trial NCT02999477?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2017-02-23. Estimated completion is 2026-01-08.

What conditions does trial NCT02999477 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT02999477?

The interventions under investigation include: Pembrolizumab (DRUG), Biopsy (PROCEDURE), Nab-Paclitaxel (DRUG).

Who is sponsoring clinical trial NCT02999477?

This trial is sponsored by Adrienne G. Waks, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02999477 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.